<DOC>
	<DOCNO>NCT02636595</DOCNO>
	<brief_summary>The purpose study evaluate effect response treatment evaluate percentage subject achieve 12-week sustained virologic response ( SVR12 ) 12 week treatment ABT-493/ABT-530 evaluate safety regimen participant chronic hepatitis C virus ( HCV ) genotype ( GT ) 4 , 5 , 6 infection .</brief_summary>
	<brief_title>The Efficacy Safety ABT-493/ABT-530 Adults With Chronic Hepatitis C Virus Genotype 4 , 5 , 6 Infection ( ENDURANCE-4 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>1 . Screening laboratory result indicate HCV GT4 , 5 , 6 infection . 2 . Chronic HCV infection . 3 . HCV treatmentna√Øve treatment experience ( IFN pegIFN without RBV ; SOF plus RBV without pegIFN ) . 4 . Noncirrhotic participant . 1 . History severe , lifethreatening significant sensitivity excipient study drug . 2 . Female pregnant , plan become pregnant study , breastfeed ; male whose partner pregnant planning become pregnant study . 3 . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol opinion investigator . 4 . Positive test result Screening hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) . 5 . Coinfection one HCV genotype .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C Genotype 4</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C Genotype 6</keyword>
	<keyword>Hepatitis C Genotype 5</keyword>
</DOC>